Radiation prevents tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑κB pathway in triple‑negative breast cancer

Pan,Chi; Shao,Shanshan; Gu,Yawen; Ni,Qingtao

doi:10.3892/or.2023.8515

Radiation prevents tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑κB pathway in triple‑negative breast cancer

Authors:
- Chi Pan
- Shanshan Shao
- Yawen Gu
- Qingtao Ni
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu 225300, P.R. China, Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu 225300, P.R. China
Published online on: March 2, 2023 https://doi.org/10.3892/or.2023.8515
Article Number: 78
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is the most common type of cancer in women. Triple‑negative BC (TNBC) constitutes 10‑15% of all BC cases and is associated with a poor prognosis. It has previously been reported that microRNA (miR)‑93‑5p is dysregulated in plasma exosomes from patients with BC and that miR‑93‑5p improves radiosensitivity in BC cells. The present study identified EphA4 as a potential target gene of miR‑93‑5p and investigated the pathway related to miR‑93‑5p in TNBC. Cell transfection and nude mouse experiments were performed to verify the role of the miR‑93‑5p/EphA4/NF‑κB pathway. Moreover, miR‑93‑5p, EphA4 and NF‑κB were detected in clinical patients. The results revealed that EphA4 and NF‑κB were downregulated in the miR‑93‑5p overexpression group. By contrast, EphA4 and NF‑κB expression levels were not significantly altered in the miR‑93‑5p overexpression + radiation group compared with those in the radiation group. Furthermore, overexpression of miR‑93‑5p with concomitant radiation therapy significantly decreased the growth of TNBC tumors in vivo. In conclusion, the present study revealed that miR‑93‑5p targeted EphA4 in TNBC through the NF‑κB pathway. However, radiation therapy prevented tumor progression by inhibiting the miR‑93‑5p/EphA4/NF‑κB pathway. Therefore, it would be interesting to elucidate the role of miR‑93‑5p in clinical research.

View Figures

View References

1	Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, Zhang H, Liu Y, Han D, Zhang N, et al: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer. 19:852020. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
3	Gao JJ and Swain SM: Luminal A breast cancer and molecular assays: A review. Oncologist. 23:556–565. 2018. View Article : Google Scholar : PubMed/NCBI
4	DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
5	Pan C, Cong A and Ni Q: Microarray data reveal potential genes that regulate triple-negative breast cancer. J Int Med Res. 50:30006052211301882022. View Article : Google Scholar : PubMed/NCBI
6	Zhang M, Zhang L, Geng A, Li X, Zhou Y, Xu L, Zeng YA, Li J and Cai C: CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression. Cell Rep. 40:1113312022. View Article : Google Scholar : PubMed/NCBI
7	Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, et al: SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest. 132:e1464712022. View Article : Google Scholar : PubMed/NCBI
8	Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, et al: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11:2436–2445. 2021. View Article : Google Scholar : PubMed/NCBI
9	Goodman CR, Seagle BL, Friedl TWP, Rack B, Lato K, Fink V, Cristofanilli M, Donnelly ED, Janni W, Shahabi S and Strauss JB: Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 4:e1801632018. View Article : Google Scholar : PubMed/NCBI
10	Alamilla-Presuel JC, Burgos-Molina AM, González-Vidal A, Sendra-Portero F and Ruiz-Gómez MJ: Factors and molecular mechanisms of radiation resistance in cancer cells. Int J Radiat Biol. 98:1301–1315. 2022. View Article : Google Scholar : PubMed/NCBI
11	Zhao W, Sun M, Li S, Chen Z and Geng D: Transcription factor ATF3 mediates the radioresistance of breast cancer. J Cell Mol Med. 22:4664–4675. 2018. View Article : Google Scholar : PubMed/NCBI
12	Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M and Greve B: miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro. Tumour Biol. 40:10104283187918872018. View Article : Google Scholar : PubMed/NCBI
13	Perez-Añorve IX, Gonzalez-De la Rosa CH, Soto-Reyes E, Beltran-Anaya FO, Del Moral-Hernandez O, Salgado-Albarran M, Angeles-Zaragoza O, Gonzalez-Barrios JA, Landero-Huerta DA, Chavez-Saldaña M, et al: New insights into radioresistance in breast cancer identify a dual function of miR-122 as a tumor suppressor and oncomiR. Mol Oncol. 13:1249–1267. 2019. View Article : Google Scholar : PubMed/NCBI
14	Feketea G, Bocsan CI, Popescu C, Gaman M, Stanciu LA and Zdrenghea MT: A review of macrophage MicroRNAs' role in human asthma. Cells. 8:422019. View Article : Google Scholar
15	Xue T, Liang W, Li Y, Sun Y, Xiang Y, Zhang Y, Dai Z, Duo Y, Wu L, Qi K, et al: Ultrasensitive detection of miRNA with an antimonene-based surface plasmon resonance sensor. Nat Commun. 10:282019. View Article : Google Scholar : PubMed/NCBI
16	Ni Q, Stevic I, Pan C, Müller V, Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci Rep. 8:129742018. View Article : Google Scholar : PubMed/NCBI
17	Pan C, Sun G, Sha M, Wang P, Gu Y and Ni Q: Investigation of miR-93-5p and its effect on the radiosensitivity of breast cancer. Cell Cycle. 20:1173–1180. 2021. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC cancer staging manual. 8th edition. Springer International Publishing; New York, NY: 2017, View Article : Google Scholar
20	Tajbakhsh A, Rivandi M, Abedini S, Pasdar A and Sahebkar A: Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review. Crit Rev Oncol Hematol. 140:17–27. 2019. View Article : Google Scholar : PubMed/NCBI
21	Fultang N, Illendula A, Chen B, Wu C, Jonnalagadda S, Baird N, Klase Z and Peethambaran B: Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity. PLoS One. 14:e2177892019. View Article : Google Scholar : PubMed/NCBI
22	Ahmed K, Koval A, Xu J, Bodmer A and Katanaev VL: Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. Cancer Lett. 449:45–55. 2019. View Article : Google Scholar : PubMed/NCBI
23	Sun XY, Han XM, Zhao XL, Cheng XM and Zhang Y: MiR-93-5p promotes cervical cancer progression by targeting THBS2/MMPS signal pathway. Eur Rev Med Pharmacol Sci. 23:5113–5121. 2019.PubMed/NCBI
24	Wu H, Liu L and Zhu JM: MiR-93-5p inhibited proliferation and metastasis of glioma cells by targeting MMP2. Eur Rev Med Pharmacol Sci. 23:9517–9524. 2019.PubMed/NCBI
25	Wang Q, Su C, Li J and Wei C: Mechanism of the enhancing effects of miR-93 on resistance of breast cancer MCF-7 cells to adriamycin. Oncol Lett. 16:3779–3783. 2018.PubMed/NCBI
26	Ge YW, Liu ZQ, Sun ZY, Yu DG, Feng K, Zhu ZA and Mao YQ: Titanium particle-mediated osteoclastogenesis may be attenuated via bidirectional ephrin-B2/eph-B4 signaling in vitro. Int J Mol Med. 42:2031–2041. 2018.PubMed/NCBI
27	Chen R, Yang X, Zhang B, Wang S, Bao S, Gu Y and Li S: EphA4 negatively regulates myelination by inhibiting schwann cell differentiation in the peripheral nervous system. Front Neurosci. 13:11912019. View Article : Google Scholar : PubMed/NCBI
28	Pan Y, Lu S, Lei L, Lamberto I and Wang Y, Pasquale EB and Wang Y: Genetically encoded FRET biosensor for visualizing EphA4 activity in different compartments of the plasma membrane. ACS Sens. 4:294–300. 2019. View Article : Google Scholar : PubMed/NCBI
29	Okyere B, Mills WR, Wang X, Chen M, Chen J, Hazy A, Qian Y, Matson JB and Theus MH: EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke. J Clin Invest. 130:1024–1035. 2020. View Article : Google Scholar : PubMed/NCBI
30	Chen X, Yang H, Zhou X, Zhang L and Lu X: MiR-93 targeting EphA4 promotes neurite outgrowth from spinal cord neurons. J Mol Neurosci. 58:517–524. 2016. View Article : Google Scholar : PubMed/NCBI
31	Kina S, Kinjo T, Liang F, Nakasone T, Yamamoto H and Arasaki A: Targeting EphA4 abrogates intrinsic resistance to chemotherapy in well-differentiated cervical cancer cell line. Eur J Pharmacol. 840:70–78. 2018. View Article : Google Scholar : PubMed/NCBI
32	de Marcondes PG and Morgado-Diaz JA: The role of EphA4 signaling in radiation-induced EMT-like phenotype in colorectal cancer cells. J Cell Biochem. 118:442–445. 2017. View Article : Google Scholar : PubMed/NCBI
33	de Marcondes PG, Bastos LG, De-Freitas-Junior JC, Rocha MR and Morgado-Díaz JA: EphA4-mediated signaling regulates the aggressive phenotype of irradiation survivor colorectal cancer cells. Tumour Biol. 37:12411–12422. 2016. View Article : Google Scholar : PubMed/NCBI
34	Sun Y, Qian J, Lu M and Xu H: Lower and reduced expression of EphA4 is associated with advanced TNM stage, lymph node metastasis, and poor survival in breast carcinoma. Pathol Int. 66:506–510. 2016. View Article : Google Scholar : PubMed/NCBI
35	Dong Y, Liu Y, Jiang A, Li R, Yin M and Wang Y: MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4. Mol Cell Biochem. 439:95–104. 2018. View Article : Google Scholar : PubMed/NCBI
36	Zheng J, Wang B, Zheng R, Zhang J, Huang C, Zheng R, Huang Z, Qiu W, Liu M, Yang K, et al: Linc-RA1 inhibits autophagy and promotes radioresistance by preventing H2Bub1/USP44 combination in glioma cells. Cell Death Dis. 11:7582020. View Article : Google Scholar : PubMed/NCBI
37	Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986.46:705–716. J Immunol. 177:7485–7496. 2006. View Article : Google Scholar : PubMed/NCBI
38	Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, et al: Non-canonical NF-κB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity. 49:490–503.e4. 2018. View Article : Google Scholar : PubMed/NCBI
39	Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA and Weinberg RA: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 16:1105–1117. 2014. View Article : Google Scholar : PubMed/NCBI